Arrowhead Pharmaceuticals (ARWR) Long-Term Deferred Tax (2012 - 2013)
Arrowhead Pharmaceuticals' (ARWR) quarterly Long-Term Deferred Tax came in at $40.2 million in Q3 2013, down 1.71% YoY from $40.9 million in Q3 2012, and down 1.71% on a QoQ basis from $40.9 million in Q3 2012.
Powered by 
Analysis
Arrowhead Pharmaceuticals (ARWR) Long-Term Deferred Tax (2012 - 2013) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 2 years of Long-Term Deferred Tax data on file, last reported at $40.2 million in Q3 2013.
- Quarterly Long-Term Deferred Tax fell 1.71% year-over-year to $40.2 million in Q3 2013, while the trailing twelve-month figure through Sep 2013 was $40.2 million (down 1.71% YoY) and the FY2013 annual result came in at $40.2 million, down 1.71% from the prior year.
- Long-Term Deferred Tax fell to $40.2 million in Q3 2013, from $40.9 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $40.9 million in Q3 2012 to a low of $40.2 million in Q3 2013.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Arrowhead Pharmaceuticals | 12.40 Bn | 10.80 Bn | - |